The efficacy of oral treatment with pramiconazole in tinea pedis and tinea cruris/corporis: two exploratory phase IIa trials

Decroix, J.; Ausma, Jannie; Cauwenbergh, G.; Borgers, M.; Wouters, Luc

doi:10.1111/j.1365-2133.2007.08420.x

Cited by 8 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For tinea infections there is little data, at present, on the use of posaconazole [ 31 ] and voriconazole [ 32 ], apart from unusual cases of deep dermatophytosis. Although newer oral drugs, such as pramiconazole in tinea corporis [ 33 ], ravuconazole in onychomycosis [ 34 ], and albaconazole [ 35 ] have been tested in vitro or by phase 1 to 2 clinical trials in dermatophyte infections, at present, they are not marketed for these indications. Griseofulvin is largely restricted to use in dermatophyte infections at a dose of 10 mg/kg/day given in tablet form [ 25 ].…”

Section: Fungal Infections Of the Skinmentioning

confidence: 99%

Therapy of Skin, Hair and Nail Fungal Infections

Hay

2018

JoF

View full text Add to dashboard Cite

Treatment of superficial fungal infections has come a long way. This has, in part, been through the development and evaluation of new drugs. However, utilising new strategies, such as identifying variation between different species in responsiveness, e.g., in tinea capitis, as well as seeking better ways of ensuring adequate concentrations of drug in the skin or nail, and combining different treatment methods, have played equally important roles in ensuring steady improvements in the results of treatment. Yet there are still areas where we look for improvement, such as better remission and cure rates in fungal nail disease, and the development of effective community treatment programmes to address endemic scalp ringworm.

show abstract

Section: Fungal Infections Of the Skinmentioning

confidence: 99%

Therapy of Skin, Hair and Nail Fungal Infections

Hay

2018

JoF

View full text Add to dashboard Cite

show abstract

“…At present, seven Phase 2a and one Phase 2b studies are completed. These studies comprise a pilot and a dose-finding trial in pityriasis versicolor and pilot trials in seborrheic dermatitis, tinea pedis, tinea cruris and tinea corporis [12,18,[129][130][131][132]. In all studies, both primary and secondary endpoints were met.…”

Section: Emerging Antimycoticsmentioning

confidence: 99%

A General Overview on Past, Present and Future Antimycotics~!2009-11-01~!2010-04-06~!2010-06-24~!

Minnebruggen¹,

François²,

Cammue³

et al. 2010

TOMYCJ

Self Cite

View full text Add to dashboard Cite

Since the discovery of amphotericin B in 1955 the armamentarium of antimycotic drugs now embraces many new chemical classes: azoles, allylamines and candins. However, despite the wide variety in chemical structure, there is a lack of diversity in terms of mechanism of action. The mechanism of action of the main classes of antimycotics as well as the therapeutic value of some representatives is discussed. Some challenges to innovation will be highlighted that when overcome will herald more effective therapeutic interventions. Finally, we will list antimycotics that are at a late stage of development.

show abstract

“…Averages of five independent repeats are expressed, together with the standard deviation (SD). Conversion factors to be used for the IC 50 s in g/ml: TRB, ϫ 0.33; MC, ϫ 0.42; ITC, ϫ 0.70; PRC, ϫ 0.66. velopment for these indications (8,9). The specific aims of this laboratory study were (i) to perform an in vitro profiling of pramiconazole and (ii) to evaluate oral and topical treatment schemes against Microsporum canis in guinea pigs and Candida albicans VVC in rats.…”

mentioning

confidence: 99%